Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort study.

ABSTRACT:

Background

Systemic immunosuppression (sISP), particularly with glucocorticoids, is commonly used among patients receiving immune checkpoint inhibitor (ICI) therapy. Although recent studies have demonstrated that sISP is associated with poor outcomes in ICI recipients, there is limited information on how the timing, dose, and duration of sISP affect overall survival (OS). This multi-cohort retrospective study aims to address these gaps.

Methods

This study included 13,086 ICI recipients from Massachusetts General Hospital, Brigham and Women's Hospital, and Dana-Farber Cancer Institute (MGBD) between May 31, 2015, and October 11, 2021. For independent validation, 26,172 ICI recipients were identified from the TriNetX database between April 30, 2010, and October 11, 2021, using

SUBMITTER: Wan G 

PROVIDER: S-EPMC12262798 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature